Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India

Background. In 2002, the Meningitis Vaccine Project (MVP) chose the Serum Institute of India, Ltd (SIIL), as its manufacturing partner to establish a product development partnership (PDP) with the Meningitis Vaccine Project (MVP). MVP was a collaboration between PATH and the World Health Organizatio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Infect Dis
Autors principals: Kulkarni, Prasad S., Socquet, Muriel, Jadhav, Suresh S., Kapre, Subhash V., LaForce, F. Marc, Poonawalla, Cyrus S.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639485/
https://ncbi.nlm.nih.gov/pubmed/26553678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ500
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars